Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01483820 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma
A Phase 1 study, sponsored by Giselle Sholler.
- Terminated
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT01483820 is a Phase 1 study that was terminated before completion, run by Giselle Sholler. The registered enrollment target is 8 participants.
The verdict
NCT01483820, a Phase 1 study, was terminated before completion, sponsored by Giselle Sholler.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this research study is to evaluate a new investigational drug (TPI 287) for neuroblastoma and medulloblastoma. An investigational drug is one that has not yet been approved by the Food and Drug Administration. This investigational drug is called TPI 287. This study will look at the tumor's response to the study drug, TPI 287, as well as the safety and tolerability of the drug. TPI 287 was shown to be effective in stopping tumor growth and was also shown to be safe in three different animal species. TPI 287 has been tested in humans in four clinical trials, and approximately 100 subjects with various types of cancers have received the drug, including a pediatric population in our previous Phase I trial.
Interventions
- DRUG TPI 287
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2011-12 |
| Est. Completion | 2014-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01483820
The ClinicalTrials.gov registry entry for NCT01483820 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Giselle Sholler, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TPI 287 is the first listed.
NCT01483820 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01483820 about?
NCT01483820 is a clinical study titled "Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma". The purpose of this research study is to evaluate a new investigational drug (TPI 287) for neuroblastoma and medulloblastoma. An investigational drug is one that has not yet been approved by the Food and Drug Administration. This investigational drug is called TPI 287. This study will look at the tu...
What is the current status of trial NCT01483820?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2011-12. Estimated completion is 2014-12.
What interventions are being tested in trial NCT01483820?
The interventions under investigation include: TPI 287 (DRUG).
Who is sponsoring clinical trial NCT01483820?
This trial is sponsored by Giselle Sholler, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.